发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia. 梳理毛细胞白血病治疗中无化疗替代方案的数据。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 DOI: 10.1080/10428194.2025.2548373
Danielle Brazel, David J Hermel, Alan Saven
{"title":"Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.","authors":"Danielle Brazel, David J Hermel, Alan Saven","doi":"10.1080/10428194.2025.2548373","DOIUrl":"https://doi.org/10.1080/10428194.2025.2548373","url":null,"abstract":"<p><p>Hairy cell leukemia (HCL) is a rare, indolent lymphoproliferative disorder that is highly responsive to purine analog therapy. While agents such as cladribine and pentostatin remain standard front-line therapies, their long-term toxicities-particularly myelosuppression and immune dysfunction-have led to growing interest in chemotherapy-free agents. Recent advances in molecular characterization of HCL, including the near-universal presence of BRAF V600E mutations, have led to an era of targeted therapeutics for the treatment of this disease. In this review, we summarize existing and emerging treatment strategies for HCL, including BRAF and MEK inhibitors, Bruton tyrosine kinase (BTK) inhibitors, anti-CD20 monoclonal antibodies, and venetoclax. These approaches offer therapeutic promise for patients with relapsed/refractory disease and for those ineligible to receive traditional chemotherapy. These regimens also result in high rates of minimal residual disease (MRD) negativity, potentially bringing us closer to the cure for HCL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. 奈拉宾、依托泊苷和环磷酰胺治疗复发/难治性t急性淋巴细胞白血病/淋巴瘤成人的单中心研究
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1080/10428194.2025.2496333
Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng, Karin M L Gaensler, Jerry C Lee, Thomas G Martin, Rebecca L Olin, Peter H Sayre, Catherine C Smith, Aaron C Logan
{"title":"Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.","authors":"Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng, Karin M L Gaensler, Jerry C Lee, Thomas G Martin, Rebecca L Olin, Peter H Sayre, Catherine C Smith, Aaron C Logan","doi":"10.1080/10428194.2025.2496333","DOIUrl":"10.1080/10428194.2025.2496333","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1749-1752"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palmitic acid adjunctive therapy upregulates bax/bcl-2 ratio and displays apoptosis as mode of anti-tumorigenic effects in multiple myeloma cells. 棕榈酸辅助治疗上调bax/bcl-2比值，并显示凋亡作为多发性骨髓瘤细胞抗肿瘤作用的模式。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 DOI: 10.1080/10428194.2025.2547246
Shraddha Kapoor, Nidhi Gupta, Karuppasamy David Raja, Imteyaz Qamar, Archana Singh, Alpana Sharma
{"title":"Palmitic acid adjunctive therapy upregulates bax/bcl-2 ratio and displays apoptosis as mode of anti-tumorigenic effects in multiple myeloma cells.","authors":"Shraddha Kapoor, Nidhi Gupta, Karuppasamy David Raja, Imteyaz Qamar, Archana Singh, Alpana Sharma","doi":"10.1080/10428194.2025.2547246","DOIUrl":"https://doi.org/10.1080/10428194.2025.2547246","url":null,"abstract":"<p><p>The promising role of palmitic acid (PA) as a tumor-suppressing agent is gaining increasing evidence. Studies support its function demonstrating a wide spectrum of anti-tumor effects, enhanced sensitivity to anti-tumor drugs, and immunity-boosting properties, which contribute to its role as a broad anti-neoplastic agent. Our study encompassed on the molecular mechanisms of Palmitic acid specifically against multiple myeloma, a hematological malignancy. We investigated its complementary effects with known chemotherapeutic agent, Lenalidomide, <i>in vitro.</i> In this study, the cytotoxicity of PA on myeloma cells correlated in a dose-dependent manner and significant apoptotic effects (<i>p</i> < 0.001) with PA were achieved in combination with Lenalidomide even at the lower doses and cell arrest at G1 phase. The apoptosis occurred successively with rise in Bax/Bcl-2 ratio & through mitochondrion membrane potential dysregulation. This study intends toward Palmitic acid as a candidate molecule having potent anti-cancer efficacy for multiple myeloma.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central nervous system relapse of core-binding factor acute myeloid leukemia. 核心结合因子急性髓系白血病的中枢神经系统复发。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-19 DOI: 10.1080/10428194.2025.2506505
J Wesley Hill, Jennifer Marvin-Peek, Koji Sasaki, Sara Bresser, Bouthaina Shbib Dabaja, Nitin Jain, Gautam Borthakur, Hussein A Abbas
{"title":"Central nervous system relapse of core-binding factor acute myeloid leukemia.","authors":"J Wesley Hill, Jennifer Marvin-Peek, Koji Sasaki, Sara Bresser, Bouthaina Shbib Dabaja, Nitin Jain, Gautam Borthakur, Hussein A Abbas","doi":"10.1080/10428194.2025.2506505","DOIUrl":"10.1080/10428194.2025.2506505","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1745-1748"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study. 卡非佐米联合R-CHOP初始治疗非生发中心弥漫性大b细胞淋巴瘤：一项多中心、单组、1/2期研究
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-21 DOI: 10.1080/10428194.2025.2504156
Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison M Winter, Wesam Ahmed, Mitchell Smith, Alex Mejia Garcia, Brenda Cooper, Ethan Krauspe, Jonathan Zhou, Taylor Brooks, Merve Kacar, Jenna Thomas, Hong Li, Xuefei Sophie Jia, Yanwen Chen, Paolo Caimi
{"title":"Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.","authors":"Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison M Winter, Wesam Ahmed, Mitchell Smith, Alex Mejia Garcia, Brenda Cooper, Ethan Krauspe, Jonathan Zhou, Taylor Brooks, Merve Kacar, Jenna Thomas, Hong Li, Xuefei Sophie Jia, Yanwen Chen, Paolo Caimi","doi":"10.1080/10428194.2025.2504156","DOIUrl":"10.1080/10428194.2025.2504156","url":null,"abstract":"<p><p>We performed a phase I/II trial to explore the safety and efficacy of carfilzomib (K) in combination with R-CHOP (KR-CHOP) in patients with diffuse large B cell lymphoma (DLBCL). A total of 48 patients were enrolled and 47 were treated. The overall response rate (ORR) was 89% (70% complete response). At a median follow-up of 31 months, 3-year Kaplan-Meier estimates of PFS and OS were 79% and 87%, respectively. Treatment with KR-CHOP for non-GC DLBCL was associated with a decreased risk of disease progression and death relative to standard of care treatment with R-CHOP with hazard ratios (HR) of 0.16 [95% confidence interval (CI) 0.04-0.58, <i>p</i> = 0.002] and 0.31 [(95% CI, 0.09 - 0.99), <i>p</i> = 0.02], respectively. The most common grade 3 or 4 adverse events (AEs) were anemia (13%), thrombocytopenia (9%) and febrile neutropenia (9%). KR-CHOP is safe and may have preferential activity in non-GC DLBCL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1700-1709"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY. 第一代和第二代酪氨酸激酶抑制剂治疗慢性粒细胞白血病慢性期患者的5年分子反应和总生存期：一项前瞻性观察性研究。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-06-22 DOI: 10.1080/10428194.2025.2495369
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S DeGutis, Ali McBride, Lori Parsons, Monica Montelongo, Jorge E Cortes
{"title":"Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.","authors":"Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S DeGutis, Ali McBride, Lori Parsons, Monica Montelongo, Jorge E Cortes","doi":"10.1080/10428194.2025.2495369","DOIUrl":"10.1080/10428194.2025.2495369","url":null,"abstract":"<p><p>SIMPLICITY (NCT01244750) was an observational study evaluating first-line (1 L) tyrosine kinase inhibitors (TKIs; dasatinib, nilotinib, imatinib) in patients with chronic myeloid leukemia in the chronic phase in routine clinical practice. At data cutoff (January 28, 2020), 810 prospective US patients were included/analyzed (dasatinib, 302; nilotinib, 264; imatinib, 244). Within 5 years, 95.4% of patients (dasatinib, 96.5%; nilotinib, 93.5%; imatinib, 95.9%) had major molecular response (<i>BCR</i>::<i>ABL1</i> ≤ 0.1%), and 79.2% (dasatinib, 79.8%; nilotinib, 81.7%; imatinib, 75.9%) deep molecular response (MR<sup>4.5</sup>; <i>BCR</i>::<i>ABL1</i> < 0.0032%) demonstrating major improvement during the study period. Of 734 patients followed for 5 years, 5-year overall survival rate was 89.8% (dasatinib, 92.9%; nilotinib, 88.6%; imatinib, 87.0%); similar to that in randomized studies. Patients who switched treatment had a poorer outcome regardless of TKI, indicating that non-kinase domain mutations may play a role. Despite missing data on outcomes in routine care, these results demonstrate excellent response and survival rates.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1615-1624"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). 髓系恶性肿瘤和肿瘤疾病协会（COMMAND）的研究结果表明，门诊低甲基化药物和venetoclax治疗新诊断的急性髓系白血病的可行性和安全性，有或没有增加。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-04-28 DOI: 10.1080/10428194.2025.2496339
Rory M Shallis, Julian J Weiss, Eric S Winer, Talha Badar, Alok Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Yasmin Abaza, Annie Im, Mark R Litzow, Nikolai A Podoltsev
{"title":"Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).","authors":"Rory M Shallis, Julian J Weiss, Eric S Winer, Talha Badar, Alok Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Yasmin Abaza, Annie Im, Mark R Litzow, Nikolai A Podoltsev","doi":"10.1080/10428194.2025.2496339","DOIUrl":"10.1080/10428194.2025.2496339","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1735-1739"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut-AML): a flow-cytometric marker for an accurate diagnostic workup. CD99在FLT3内部串联重复的急性髓系白血病（FLT3- itdmut - aml）中的表达：一种用于准确诊断的流式细胞术标记
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-04-28 DOI: 10.1080/10428194.2025.2497392
Alessandro Laganà, Deborah Kasmi, Daniela Diverio, Maria Laura Bisegna, Ida Carmosino, Emilia Scalzulli, Clara Minotti, Maria Laura Milani, Sonia Buffolino, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris
{"title":"CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD<sup>mut</sup>-AML): a flow-cytometric marker for an accurate diagnostic workup.","authors":"Alessandro Laganà, Deborah Kasmi, Daniela Diverio, Maria Laura Bisegna, Ida Carmosino, Emilia Scalzulli, Clara Minotti, Maria Laura Milani, Sonia Buffolino, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris","doi":"10.1080/10428194.2025.2497392","DOIUrl":"10.1080/10428194.2025.2497392","url":null,"abstract":"<p><p>Internal tandem duplications of FLT3 (FLT3-ITD) in acute myeloid leukemia (AML) are associated with poor outcomes. CD99 is frequently overexpressed in AML and emerged as potential diagnostic marker. Ninety consecutive newly diagnosed AML patients were retrospectively analyzed. Immunophenotypic profiles were correlated with molecular assessment. Patients were categorized into FLT3-ITD<sup>mut</sup> (28.9%) and FLT3<sup>wt</sup> (71.1%). CD99 was expressed in 100% of FLT3-ITD<sup>mut</sup>-AML compared to 48% in FLT3<sup>wt</sup> cases. FLT3-ITD<sup>mut</sup>-AML exhibited higher CD99 expression percentage. CD34 expression was lower in FLT3-ITD<sup>mut</sup>-AML, with a positivity rate of 31% versus 83% in FLT3<sup>wt</sup> cases. Multivariate analysis confirmed that CD99 positivity (OR 17.67; <i>p</i> = 0.010) and CD34 negativity (OR 10.00; <i>p</i> = 0.039) were independently associated with FLT3-ITD<sup>mut</sup>-AML. CD99 and CD34 displayed NPVs of 100% and 86.9%, respectively, with moderate PPVs (45.6% and 62.1%) for the diagnosis of FLT3-ITD<sup>mut</sup>-AML. CD99 is a highly reliable marker in FLT3-ITD<sup>mut</sup>-AML and its absence virtually excludes the presence of a FLT3-ITD mutation.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1669-1674"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C. 白血病患者对BTK抑制剂的耐药性：BTK中的半胱氨酸481等于BTK异构体BTK- c中的半胱氨酸515。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-06-12 DOI: 10.1080/10428194.2025.2518433
C I Edvard Smith
{"title":"Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.","authors":"C I Edvard Smith","doi":"10.1080/10428194.2025.2518433","DOIUrl":"10.1080/10428194.2025.2518433","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1762-1763"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance. 与阿卡拉布替尼耐药性相关的CLL患者BTK C515残基的新分离突变
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-16 DOI: 10.1080/10428194.2025.2501269
Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kiriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis
{"title":"Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance.","authors":"Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kiriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis","doi":"10.1080/10428194.2025.2501269","DOIUrl":"10.1080/10428194.2025.2501269","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1753-1755"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信